Natalizumab
- PDF / 141,374 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 84 Downloads / 135 Views
1
S
Progressive multifocal leukoencephalopathy: case report A 43-year-old woman developed progressive multifocal leukoencephalopathy (PML) during treatment with natalizumab for multiple sclerosis. The woman had been receiving natalizumab [dosage not stated] for 2 years and presented with a small PML-like lesion. She developed right-sided hemiparesis and aphasia, and was subsequently hospitalised. Investigations revealed JC virus DNA in the woman’s cerebrospinal fluid. The woman began plasmapheresis, which was subsequently discontinued because of acute deterioration due to a difficult to treat severe status epilepticus. During intensive care, she experienced substantial clinical disease progression and an MRI scan revealed PML changes affecting the whole brain, including the brain stem. Local IgG synthesis increased substantially 1 month after admission. Two months after admission, there was an increase in JC virus DNA levels and the woman was transferred to rehabilitation. Although JC virus DNA levels decreased 4 months after admission, no substantial clinical improvement was observed and she continues to remain in a vegetative condition. Ziemssen T, et al. Unusual Development of Progressive Multifocal Leukoencephalopathy with High JC Virus Titer in a Patient with Multiple Sclerosis after 2 Years of Natalizumab Therapy. 62nd Annual Meeting of the American Academy of Neurology : abstr. P04.199, 14 Apr 2010. Available from: URL: http:/ 803013807 /www.abstracts2view.com/aan - Germany
0114-9954/10/1301-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 15 May 2010 No. 1301
Data Loading...
